The firm recently described circumstances in which the fraction of host or donor DNA could be altered, and plans new approaches to data interpretation.
The collaboration in particular focuses on the UK market introduction of SphingoTec's point-of-care tests for use of novel biomarkers in critical care.
KidneyIntelX is designed to help assess the risk of progressive decline in kidney function in patients with type 2 diabetes and chronic kidney disease.
The London-based firm hopes to also show the clinical utility of its KidneyIntelX assay for predicting the risk of the patients' progressive kidney decline.
The firm intends to use about $25 million to $30 million of the net proceeds for the continued development and planned commercialization of its KidneyIntelX platform.
